First Time Loading...

BRAIN Biotech AG
XETRA:BNN

Watchlist Manager
BRAIN Biotech AG Logo
BRAIN Biotech AG
XETRA:BNN
Watchlist
Price: 2.14 EUR 0.94% Market Closed
Updated: Jul 27, 2024
Have any thoughts about
BRAIN Biotech AG?
Write Note

Intrinsic Value

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. [ Read More ]

The intrinsic value of one BNN stock under the Base Case scenario is 7.26 EUR. Compared to the current market price of 2.14 EUR, BRAIN Biotech AG is Undervalued by 71%.

Key Points:
BNN Intrinsic Value
Base Case
7.26 EUR
Undervaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BRAIN Biotech AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BNN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BRAIN Biotech AG

Current Assets 29.3m
Cash & Short-Term Investments 10.4m
Receivables 8.8m
Other Current Assets 10.1m
Non-Current Assets 43.9m
Long-Term Investments 1.1m
PP&E 28.2m
Intangibles 14.6m
Other Non-Current Assets 78k
Current Liabilities 14.6m
Accounts Payable 4.5m
Other Current Liabilities 10.1m
Non-Current Liabilities 40.3m
Long-Term Debt 4.3m
Other Non-Current Liabilities 36m
Efficiency

Earnings Waterfall
BRAIN Biotech AG

Revenue
56.3m EUR
Cost of Revenue
-24m EUR
Gross Profit
32.3m EUR
Operating Expenses
-37.5m EUR
Operating Income
-5.2m EUR
Other Expenses
-2.9m EUR
Net Income
-8m EUR

Free Cash Flow Analysis
BRAIN Biotech AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BNN Profitability Score
Profitability Due Diligence

BRAIN Biotech AG's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
ROIC is Increasing
27/100
Profitability
Score

BRAIN Biotech AG's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BNN Solvency Score
Solvency Due Diligence

BRAIN Biotech AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
41/100
Solvency
Score

BRAIN Biotech AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNN Price Targets Summary
BRAIN Biotech AG

Wall Street analysts forecast BNN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNN is 9.95 EUR with a low forecast of 4.14 EUR and a high forecast of 15.75 EUR.

Lowest
Price Target
4.14 EUR
94% Upside
Average
Price Target
9.95 EUR
365% Upside
Highest
Price Target
15.75 EUR
636% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BNN?

Click here to dive deeper.

Competitive Landscape

Price Appreciation

BNN Price
BRAIN Biotech AG

1M 1M
-13%
6M 6M
-43%
1Y 1Y
-53%
3Y 3Y
-79%
5Y 5Y
-76%
10Y 10Y
-76%
Annual Price Range
2.14
52w Low
2.11
52w High
4.75
Price Metrics
Average Annual Return -6.17%
Standard Deviation of Annual Returns 28.4%
Max Drawdown -84%
Shares Statistics
Market Capitalization 46.8m EUR
Shares Outstanding 21 847 495
Percentage of Shares Shorted
N/A

BNN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

BRAIN Biotech AG Logo
BRAIN Biotech AG

Country

Germany

Industry

Chemicals

Market Cap

46.8m EUR

Dividend Yield

0%

Description

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

Contact

HESSEN
Zwingenberg
Darmstaedter Strasse 34-36
+49625193310.0
https://www.brain-biotech.de/

IPO

2016-02-09

Employees

293

Officers

Chairman of the Management Board & CEO
Mr. Adriaan Moelker
Co-Founder
Mr. Ulrich Putsch
CFO & Member of Management Board
Mr. Michael Schneiders
Vice President of Human Resources & Processes
Dr. Ute Dechert
Consultant
Dr. Jurgen Eck
MD & Executive VP
Dr. Martin Langer
Show More
VP and Head of Research & Development - Zwingenberg
Dr. Alexander Pelzer
Head of Group Finance
Mr. Robbert Michael Hoekstra
Technical Lead of Genome Editing Development
Mr. Paul Scholz
Show Less

See Also

Discover More
What is the Intrinsic Value of one BNN stock?

The intrinsic value of one BNN stock under the Base Case scenario is 7.26 EUR.

Is BNN stock undervalued or overvalued?

Compared to the current market price of 2.14 EUR, BRAIN Biotech AG is Undervalued by 71%.